Related Experiment Video
Updated: Aug 22, 2025
09:31
Surface Properties of Synthesized Nanoporous Carbon and Silica Matrices
Published on: March 27, 2019
9.6K
Mesoporous silicas in materials engineering: Nanodevices for bionanotechnologies
Elisabetta Mazzotta1, Marzia De Santo2, Domenico Lombardo3
1Experimental Neurology Unit, School of Medicine and Surgery and Milan Center for Neuroscience, University of Milano-Bicocca, Via Cadore 48, 20900 Monza, Italy.
Materials Today. Bio
|November 7, 2022
Summary
Mesoporous silica nanoparticles offer significant opportunities for developing nanodevices in bionanotechnology, particularly for targeted cancer treatment delivery. This review explores their design, challenges, and potential for clinical translation in cancer therapy.
Area of Science:
- Bionanotechnology
- Materials Science
- Nanomedicine
Background:
- Mesoporous silica nanoparticles (MSNs) are versatile nanomaterials with tunable properties.
- Their application in nanodevices for bionanotechnology is rapidly expanding.
- Targeted drug delivery, especially for cancer, is a key area of development.
Purpose of the Study:
- To review the opportunities of MSNs in nanodevice development for bionanotechnology.
- To critically assess the state-of-the-art in cancer-related applications.
- To discuss challenges and solutions for selective anticancer agent administration.
Main Methods:
- Literature review and critical analysis of existing research.
- Discussion of design principles for MSN-based nanodevices.
- Evaluation of factors limiting targeted delivery and proposed technical solutions.
Main Results:
- MSNs show great promise for selective anticancer agent delivery to tumor tissues.
- Challenges in targeting difficult tissues and advanced applications like immunotherapy, diagnostics, theranostics, and gene therapy were addressed.
- Technical solutions for overcoming limitations in drug delivery were identified.
Conclusions:
- The translation of MSN-based nanodevices from research to clinical practice and market is feasible.
- Further research and development can overcome current limitations for broader clinical adoption.
- MSNs represent a significant advancement in nanomedicine for oncology and beyond.
